Genetic heterogeneity and evolutionary history of high-grade ovarian carcinoma and matched distant metastases
-
Published:2020-02-26
Issue:8
Volume:122
Page:1219-1230
-
ISSN:0007-0920
-
Container-title:British Journal of Cancer
-
language:en
-
Short-container-title:Br J Cancer
Author:
Masoodi Tariq,Siraj Sarah,Siraj Abdul K.,Azam Saud,Qadri Zeeshan,Parvathareddy Sandeep K.,Tulbah Asma,Al-Dayel Fouad,AlHusaini Hamed,AlOmar Osama,Al-Badawi Ismail A.,Alkuraya Fowzan S.,Al-Kuraya Khawla S.
Abstract
Abstract
Background
High-grade serous ovarian carcinoma (HGSOC) is the most frequent type of ovarian carcinoma, associated with poor clinical outcome and metastatic disease. Although metastatic processes are becoming more understandable, the genomic landscape and metastatic progression in HGSOC has not been elucidated.
Methods
Multi-region whole-exome sequencing was performed on HGSOC primary tumours and their metastases (n = 33 tumour regions) from six patients. The resulting somatic variants were analysed to delineate tumour evolution and metastatic dissemination, and to compare the repertoire of events between primary HGSOC and metastasis.
Results
All cases presented branching evolution patterns in primary HGSOC, with three cases further showing parallel evolution in which different mutations on separate branches of a phylogenetic tree converge on the same gene. Furthermore, linear metastatic progression was observed in 67% of cases with late dissemination, in which the metastatic tumour mostly acquires the same mutational process active in primary tumour, and parallel metastatic progression, with early dissemination in the remaining 33.3% of cases. Metastatic-specific SNVs were further confirmed as late dissemination events. We also found the involvement of metastatic-specific driver events in the Wnt/β-catenin pathway, and identified potential clinically actionable events in individual patients of the metastatic HGSOC cohort.
Conclusions
This study provides deeper insights into clonal evolution and mutational processes that can pave the way to new therapeutic targets.
Publisher
Springer Science and Business Media LLC
Subject
Cancer Research,Oncology
Reference53 articles.
1. Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J. & Jemal, A. Global cancer statistics, 2012. CA: Cancer J. Clin. 65, 87–108 (2015). 2. Jacobs, I. J., Menon, U., Ryan, A., Gentry-Maharaj, A., Burnell, M., Kalsi, J. K. et al. Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet 387, 945–956 (2016). 3. Bowtell, D. D., Bohm, S., Ahmed, A. A., Aspuria, P. J., Bast, R. C. Jr., Beral, V. et al. Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nat. Rev. Cancer 15, 668–679 (2015). 4. McPherson, A., Roth, A., Laks, E., Masud, T., Bashashati, A., Zhang, A. W. et al. Divergent modes of clonal spread and intraperitoneal mixing in high-grade serous ovarian cancer. Nat. Genet. 48, 758–767 (2016). 5. Klein, C. A. Parallel progression of primary tumours and metastases. Nat. Rev. Cancer 9, 302–312 (2009).
Cited by
61 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
|
|